Sign up
Pharma Capital

Aurora Cannabis acquires equity stake in CTT Pharmaceutical as it explores oral cannabis strips

Cannabis companies Aphria and Canopy Growth have also looked into fast-dissolving oral strips
Marijuana farm
Aurora is looking to apply CTT’s dissolving wafer technology to the cannabis industry

Aurora Cannabis Inc (TSX:ACB,OTCQX:ACBFF) has acquired an equity stake in CTT Pharmaceutical Holdings Inc (OTCMKTS:CTTH) as it looks into new delivery methods for cannabis.

The Canadian cannabis giant converted its US$1mln loan into a 9.14% equity ownership stake with the option to increase its stake to 42.5%.

Shares of Aurora jumped more than 3% to US$6.51 while shares of CTT surged more than 45% to US$1.02 in morning trading.

READ: Canopy Growth inks deal for rights to CURE Pharmaceutical’s oral cannabis strips

CTT develops a patented drug delivery method involving a thin wafer that dissolves when placed under the tongue.

“CTT’s innovative technology has the potential to produce great utility when applied to the cannabis industry, and we are encouraged with our joint progress towards establishing a long-term commercial arrangement with CTT to market this exciting technology,” said Aurora CEO Terry Booth in the company’s press release.

Aurora joins other cannabis companies that have been looking into delivering cannabis through fast-dissolving oral strips, including Aphria Inc (TSX:APH, OTCQB:APHQF) and Canopy Growth Corp (TSX:WEED, NYSE:CGC).



Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.